HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+7.32%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.65B
AUM Growth
+$1.65B
(-3.7%)
Cap. Flow
-$96.8M
Cap. Flow
% of AUM
-5.88%
Top 10 Holdings %
Top 10 Hldgs %
56.48%
Holding
62
New
19
Increased
12
Reduced
10
Closed
20
Top Buys
| 1 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
$105M |
| 2 |
Zimmer Biomet
ZBH
|
$92.3M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$65M |
| 4 |
DexCom
DXCM
|
$59.4M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$53.4M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$129M |
| 2 |
SRCL
Stericycle Inc
SRCL
|
$108M |
| 3 |
RAD
Rite Aid Corporation
RAD
|
$82.1M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$74.4M |
| 5 |
AET
Aetna Inc
AET
|
$71.1M |
Sector Composition
| 1 | Healthcare | 71.96% |
| 2 | Financials | 0% |
| 3 | Industrials | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCR
1
DELISTED
CR Bard Inc.
BCR
| $133M | 8.05% | 700,000 +150,000 | +27% | +$28.4M |
|
2
Eli Lilly
LLY
$657B
| $112M | 6.78% | 1,325,000 +325,000 | +33% | +$27.4M |
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $111M | 6.75% | 2,300,000 +400,000 | +21% | +$19.3M |
|
|
BXLT
4
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $105M | 6.38% | +2,690,440 | New | +$105M |
|
5
Labcorp
LH
$23.1B
| $98.9M | 6.01% | 800,000 +250,000 | +45% | +$30.9M |
|
|
6
Zimmer Biomet
ZBH
$21B
| $92.3M | 5.61% | +900,000 | New | +$92.3M |
|
|
AKRX
7
DELISTED
Akorn, Inc.
AKRX
| $74.6M | 4.53% | 2,000,000 -325,000 | -14% | -$12.1M |
|
8
Abbott
ABT
$231B
| $74.5M | 4.52% | 1,658,540 -591,460 | -26% | -$26.6M |
|
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $65M | 3.95% | +990,510 | New | +$65M |
|
|
CVRS
10
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $64.1M | 3.9% | 19,981,655 | – | – |
|
|
11
DexCom
DXCM
$29.5B
| $61.4M | 3.73% | 750,000 +725,000 | +2,900% | +$59.4M |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $59.4M | 3.61% | 471,970 -178,030 | -27% | -$22.4M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $53.4M | 3.24% | +1,525,000 | New | +$53.4M |
|
14
Pfizer
PFE
$141B
| $50.7M | 3.08% | 1,570,130 -1,104,870 | -41% | -$35.7M |
|
15
Viatris
VTRS
$12.3B
| $48.7M | 2.96% | +901,510 | New | +$48.7M |
|
16
Cencora
COR
$56.5B
| $47.6M | 2.89% | +459,140 | New | +$47.6M |
|
17
Brookdale Senior Living
BKD
$1.83B
| $46.2M | 2.8% | 2,500,000 +575,000 | +30% | +$10.6M |
|
18
Universal Health Services
UHS
$11.6B
| $43.8M | 2.66% | 366,390 -108,610 | -23% | -$13M |
|
19
Quest Diagnostics
DGX
$20.3B
| $37.3M | 2.27% | +524,650 | New | +$37.3M |
|
20
Incyte
INCY
$16.5B
| $34.9M | 2.12% | +322,030 | New | +$34.9M |
|
21
Icon
ICLR
$13.8B
| $31.1M | 1.89% | +400,000 | New | +$31.1M |
|
22
Collegium Pharmaceutical
COLL
$1.22B
| $28.2M | 1.71% | 1,025,000 +75,000 | +8% | +$2.06M |
|
|
SGNT
23
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $27.8M | 1.69% | 1,750,000 +500,000 | +40% | +$7.96M |
|
24
Acadia Pharmaceuticals
ACAD
$4.38B
| $20.9M | 1.27% | 586,564 -92,136 | -14% | -$3.28M |
|
|
MNK
25
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $18.6M | 1.13% | +249,390 | New | +$18.6M |
|